Recombinant Human OX40/TNFRSF4 Mouse IgG2a Fc Protein, CF

When Recombinant Human OX40 Ligand/TNFSF4 Protein (1054-OX) is immobilized at 250 ng/mL, the concentration of Recombinant Human OX40/TNFRSF4 Mouse IgG2a Fc Chimera (Catalog # 10649-OX) that produces 50% optimal binding response is found to be approximately 2.5-15 ng/mL.

2 μg/lane of Recombinant Human OX40/TNFRSF4 mFc Chimera Protein (Catalog # 10649-OX) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 60-70 kDa and 120-140 kDa, respectively.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human OX40/TNFRSF4 Mouse IgG2a Fc Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human OX40 Ligand/TNFSF4 Protein (Catalog # 1054-OX) is immobilized at 250 ng/mL, the concentration of Recombinant Human OX40/TNFRSF4 Mouse IgG2a Fc Chimera that produces 50% optimal binding response is found to be approximately 2.5-15 ng/mL.
• Source: Mouse myeloma cell line, NS0-derived human OX40/TNFRSF4 protein
  

  Human OX40/TNFRSF4 (Leu29-Ala216) Accession # NP_003318.1	IEGRMDP	Mouse IgG2a (Glu98-Lys330)
  N-terminus		C-terminus

• Accession #: NP_003318.1
• N-terminal Sequence: Leu29
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 47 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 60-70 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 250 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human OX40/TNFRSF4 Mouse IgG2a Fc Protein, CF

• CSIF
• CSIFMGC126450
• Cytokine synthesis inhibitory factor
• GVHDS
• IL10
• IL-10
• IL10A
• IL-10MGC126451
• interleukin 10
• interleukin-10
• TGIF

Background

OX40 (CD134; TNFRSF4) is a T cell co-stimulatory molecule of the TNF receptor superfamily that coordinates with other co-stimulators (CD28, CD40, CD30, CD27 and 4-1BB) to manage the activation of the immune response (1-3). Human OX40 is a 48 kDa type I transmembrane glycoprotein with a 28 amino acid (aa) signal sequence, a 185 aa extracellular domain (ECD) that contains a cysteine-rich region, a 20 aa transmembrane segment, and a 41 aa cytoplasmic domain (4). The ECD of human OX40 shares 63% sequence identity with the ECD of mouse and rat OX40. OX40 is up-regulated on CD4+ and CD8+ T cells upon engagement of the TCR by antigen presenting cells along with co-stimulation by CD40-CD40 Ligand and CD28-B7 (5, 6). OX40 Ligand is primarily expressed on antigen presenting cells (5). OX40 Ligand engagement of OX40 on activated CD4+ T cells results in increased T cell survival, proliferation, and cytokine production. It also inhibits the conversion of effector T cells into immunosuppressive regulatory T cells (Tregs) and can promote the maintenance of and recall response in memory T cells (3, 7-10). OX40 is constitutively expressed on Tregs and enhances the sensitivity of Tregs to IL-2, thus promoting Treg proliferation. OX40 has also been shown to decrease the cells’ immunosuppressive activity on effector T cells (11-14). OX40-OX40 Ligand signaling is involved in allergic airway inflammation, graft-versus-host disease and autoimmune disease (6, 15, 16). Mutations in OX40 and OX40 Ligand are associated with cardiovascular disease (17, 18).

1. Hori, T. (2006) Int. J. Hematol. 83:17.
2. Latza, U. et al. (1994) Eur. J. Immunol. 24:677.
3. Salek-Ardakani, S. et al. (2003) J. Exp. Med. 198:315.
4. al-Shamkhani, A. et al. (1996) Eur. J. Immunol. 26:1695.
5. Moran, A.E. et al. (2013) Curr. Opin. Immunol. 25:230.
6. Gramaglia, I. et al. (1998) J. Immunol. 161:6510.
7. Xiao, X. et al. (2008) J. Immunol. 181:3193.
8. So, T. and M. Croft (2007) J. Immunol. 179:1427.
9. Mousavi, S.F. et al. (2008) J. Immunol. 181:5990.
10. Bansal-Pakala, P. et al. (2001) Nat. Med. 7:907.
11. Piconese, S. et al. (2010) Eur. J. Immunol. 40:2902.
12. Griseri, T. et al. (2010) J. Exp. Med. 207:699.
13. Xiao, X. et al. (2012) J. Immunol. 188:892.
14. Vu, M.D. et al. (2007) Blood 110:2501.
15. Damayanti, T. et al. (2010) Am. J. Respir. Crit. Care Med. 181:688.
16. Xiao, X. et al. (2012) Nat. Immunol. 13:981.
17. Nakano, M. et al. (2010) Cardiovasc. Res. 88:539.
18. Ishii, N. et al. (2010) Adv. Immunol. 105:63.
19. Godfrey, W.R. et al. (1994) J. Exp. Med. 180:757

Bioinformatics

• Uniprot:
  • NP_003318.1()